Magnesium Sulfate Pediatric Dose — Asthma & Respiratory
Magnesium sulfate is an inorganic salt that acts as a bronchodilator by inhibiting smooth muscle contraction through calcium channel antagonism and reducing acetylcholine release at the neuromuscular junction. In pediatric practice, it is used as an adjunct therapy for acute severe or life-threatening asthma exacerbations that are refractory to initial bronchodilator therapy. Its role is well recognized in both PALS and emergency department protocols for pediatric respiratory distress.
Pediatric Dosing
- Route: Intravenous (IV)
- Dose: 25–75 mg/kg per dose, administered over 20 minutes
- Maximum single dose: 2 g (2,000 mg)
The dose range allows titration based on severity. Most centers initiate at 25–50 mg/kg for moderate-to-severe exacerbations, escalating toward 75 mg/kg in life-threatening bronchospasm, not to exceed the 2 g cap regardless of weight.
Worked example: For a 20 kg child: 20 × 50 mg/kg = 1,000 mg (1 g) total — well within the 2 g maximum. For a 30 kg child at 75 mg/kg: 30 × 75 = 2,250 mg — dose-cap applies, administer 2 g.
Indications and Clinical Context
Magnesium sulfate is indicated as adjunctive therapy in pediatric patients with acute severe asthma exacerbations who show an inadequate response to first-line treatment with inhaled short-acting beta-agonists (e.g., albuterol) and systemic corticosteroids. It is classified as a resuscitation-adjunct/bronchodilator in this context. Current PALS and major emergency medicine guidelines support its use in severe exacerbations (PEFR or FEV₁ <40% predicted, or clinical deterioration despite aggressive initial therapy) to reduce the likelihood of hospital admission and respiratory failure.
The drug is particularly valuable in the PICU or emergency setting when the patient is approaching respiratory fatigue or when non-invasive ventilatory support is being considered. Its bronchodilatory effect complements but does not replace beta-agonist and anticholinergic therapy.
Administration and Monitoring
Administer magnesium sulfate intravenously over 20 minutes as a diluted infusion; rapid infusion increases the risk of hypotension and flushing. Confirm IV or IO access prior to administration — IO is acceptable in emergent situations when IV access is unavailable. Consult institutional protocol for dilution concentration and compatible fluids (typically diluted in normal saline or D5W).
- Monitor: Blood pressure, heart rate, respiratory rate, and oxygen saturation continuously during infusion
- Adverse effects: Hypotension, flushing, nausea, transient muscle weakness, and bradycardia — most are infusion-rate dependent
- Contraindications/cautions: Use with caution in renal impairment (risk of accumulation); calcium gluconate should be available as an antidote for magnesium toxicity
- Max single dose: 2 g — do not exceed regardless of calculated per-kg dose
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.